drugset / Trial / NCT00623779
Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATECEGATRAN METOXIL | Small molecule | — | Oral |
| Subject | Aspirin | Small molecule | — | Oral |